Jeffrey Tong

Jeff Tong is interim CEO of Ambys Medicines and a venture partner with Third Rock Ventures where he focuses on drug discovery and development across the portfolio. He brings significant operational experience in building and growing early-stage biotechnology companies. He is currently a board member of Ambys Medicines and Nurix and prior to joining Third Rock was executive chairman of the board of Delinia until its acquisition by Celgene. From 2010 to 2015, Jeff was the president and CEO of Nora Therapeutics. Prior to that, he was a member of the founding management team at Infinity Pharmaceuticals where he led its corporate as well as product development activities. Over the course of his career, Jeff has raised significant capital from both equity markets and pharma partnerships, led teams from preclinical through phase 3 development, and developed integrated science/business strategies for building innovative biotechnology companies. Earlier in his career, Jeff worked at McKinsey & Co. and was a founding researcher at the Harvard Bauer Center for Genomics Research.